Amrutanjan Health Care Limited

BSE: AMRUTANJAN590006ISIN INE098F01031

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹511.45+12.10 (+2.42%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹744.00
52W low: ₹476.85
Off 52W high: -31.26%
1M return: -1.07%
3M return: -2.62%
6M return: -6.69%
1Y return: -28.64%
20D avg volume: 1,543
50 DMA: ₹503.89
200 DMA: ₹542.69

Key ratios Standalone

Market cap: ₹1,495 Cr
Current price: ₹511.45
52W high / low: ₹744.00 / ₹476.85
Face value: ₹1.00
P/E: 25.80
P/B: 4.97
EPS (TTM): ₹19.82
Book value / share: ₹102.91
ROE: 19.24%
ROCE: 20.40%
Operating margin: 19.70%
Net margin: 12.78%
Debt / equity: 0.00
Net debt: ₹-11.27 Cr
Interest cover: 390.45
Dividend yield: 0.96%
Dividend / share (TTM): ₹4.90
Payout: 24.72%
Cash conversion cycle: 19.6 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	135.18	102.97	149.77	141.04	117.70	94.05	135.41	122.75	109.92	83.74	127.06	116.99
	3.02	3.81	4.73	4.12	4.30	4.43	4.82	4.36	4.05	4.45	4.95	3.76
	138.20	106.78	154.50	145.16	122.00	98.47	140.23	127.11	113.96	88.19	132.01	120.76
	115.10	98.69	125.88	117.54	102.78	87.18	119.38	101.12	98.02	81.84	112.41	97.05
	46.72	25.76	31.30	28.77	25.12	21.24	34.95	25.98	18.16	21.51	28.96	28.75
	17.54	36.08	40.98	33.29	35.19	31.16	30.93	30.46	34.48	27.31	31.05	27.16
	18.00	17.62	15.65	16.15	15.95	16.01	16.02	14.70	14.52	13.86	12.46	12.05
	0.04	0.04	0.05	0.05	0.05	0.05	0.04	0.06	0.06	0.06	0.05	0.05
	3.49	1.92	1.61	1.62	1.56	1.53	1.62	1.66	1.65	1.59	1.53	1.58
	32.84	24.82	35.05	35.93	27.57	20.19	32.70	—	—	13.55	19.43	13.17
	23.10	8.10	28.62	27.62	19.21	11.29	20.86	25.99	15.94	6.35	19.61	23.71
	0.00	-2.03	-7.61	-1.25	0.00	0.00	0.00	—	—	—	—	—
	23.10	6.07	21.02	26.36	19.21	11.29	20.86	25.99	15.94	6.35	19.61	23.71
	5.82	1.70	4.82	6.91	5.25	2.98	5.68	6.74	4.14	1.73	5.95	6.26
	17.28	4.37	16.19	19.45	13.96	8.31	15.18	19.25	11.80	4.62	13.66	17.45
	5.98	1.51	5.60	6.73	4.83	2.87	5.25	6.66	4.08	1.60	4.72	6.05
Key metrics
	26.63	8.03	22.68	28.03	20.82	12.87	22.52	27.71	17.65	8.00	21.19	25.34
	19.70%	7.80%	15.10%	19.90%	17.70%	13.70%	16.60%	22.60%	16.10%	9.60%	16.70%	21.70%
	12.80%	4.20%	10.80%	13.80%	11.90%	8.80%	11.20%	15.70%	10.70%	5.50%	10.80%	14.90%
	5.80%	—	5.50%	—	5.50%	—	6.20%	—	—	—	—	—
	14.90%	9.50%	10.60%	14.90%	7.10%	12.30%	6.60%	4.90%	—	—	—	—
	23.80%	-47.40%	6.70%	1.00%	18.30%	79.90%	11.10%	10.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	528.96	502.55	451.82	421.23	379.64	405.84
	15.68	17.57	17.68	16.35	14.54	15.38
	544.64	520.13	469.50	437.58	394.18	421.23
	457.21	433.38	400.36	375.63	340.53	330.65
	132.55	106.43	100.60	103.36	105.17	121.86
	127.89	140.63	123.18	106.31	78.53	64.10
	67.42	63.76	59.10	47.69	48.81	48.23
	0.18	0.20	0.22	0.16	0.08	0.48
	8.64	6.32	6.53	6.06	5.21	3.80
	128.64	118.74	111.31	57.48	51.87	42.64
	87.44	86.75	69.13	61.95	53.65	90.58
	-10.89	-8.86	0.00	—	—	—
	76.55	77.89	69.13	61.95	53.65	90.58
	19.25	19.97	18.30	16.97	13.81	23.39
	57.29	57.92	50.84	44.97	39.84	67.19
	19.82	20.03	17.58	15.56	13.65	23.05
Key metrics
	85.37	84.41	75.88	68.17	58.94	94.86
	16.14%	16.80%	16.80%	16.20%	15.50%	23.40%
	10.83%	11.50%	11.30%	10.70%	10.50%	16.60%
	—	20.40%	20.60%	—	—	—
	12.57%	11.20%	7.30%	11.00%	-6.50%	—
	1.04%	13.90%	13.10%	12.90%	-40.70%	—
	—	-19.03	15.35	—	—	—
	—	0.62	1.00	—	—	—
	—	0.00	0.00	—	—	—
	—	-11.27	-10.16	—	—	—
	—	19.6	11.3	—	—	—
Balance sheet
	—	508.89	421.39	—	—	—
	—	291.65	290.67	—	—	—
	—	11.27	10.16	—	—	—
	—	60.64	55.82	—	—	—
	—	37.35	27.26	—	—	—
	—	14.91	8.26	—	—	—
	—	49.81	47.73	—	—	—
	—	70.89	69.04	—	—	—
	—	126.18	84.58	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	370.23	326.61	—	—	—
Cash flow
	—	35.97	50.90	—	—	—
	—	-21.23	-30.97	—	—	—
	—	-13.62	-13.49	—	—	—
	—	55.00	35.55	—	—	—

Compounded growth

Sales CAGR 3Y: +9.80%
Sales CAGR 5Y: —
Profit CAGR 3Y: +13.28%
Profit CAGR 5Y: —
Sales YoY (TTM): +12.57%
Profit YoY (TTM): +1.04%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 46.51%

Quarter	September 2026	June 2026
Promoter %	46.51%	46.51%

Holder	Type	Holding	Previous	Change
GOODHEALTH HOLDINGS PRIVATE LIMITED	Promoter Group	20.15%	20.15%	0.00%
SAMBHUPRASAD SIVALENKA	Promoter	10.34%	10.34%	0.00%
RAMAA PRABHAKAR ARIKIREVULA	Promoter	7.76%	7.76%	0.00%
SAMBHU PRASAD SIVALENKA	Promoter	3.60%	3.60%	0.00%
ISIF EQUITY LONG-SHORT FUND	Public	3.47%	—	—
RAMALINGAM GANTI	Promoter	2.53%	2.53%	0.00%
ADITYA DEORAH	Public	2.31%	—	—
AMULYA KAMAKSHI PRIYA ARIKIREVULA	Promoter	2.13%	2.13%	0.00%
PARI WASHINGTON INDIA MASTER FUND, LTD	Public	2.02%	—	—
Investor Education and Protection Fund (IEPF)	Public	1.50%	1.50%	0.00%
DIPAK KANAYALAL SHAH	Public	1.16%	1.12%	+0.04%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Amrutanjan Health Care Limited S	1,495	511.45	25.80	20.40%	+12.57% TTM	+1.04% TTM	-28.64%

Filings & corporate actions

Recent announcements

Investor Presentation for the Quarter Ended 30th September 20263 Nov 2026 · Company Update / General
Record Date for the first interim dividend 2026-273 Nov 2026 · Corp. Action / Record Date
Outcome for the Unaudited Financial Results for the Quarter and Half Year Ended September 30, 20263 Nov 2026 · Board Meeting / Outcome of Board Meeting
Amrutanjan Health Care Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Financial ....27 Oct 2026 · Board Meeting / Board Meeting
Intimation of ESG Ratings9 Oct 2026 · Company Update / General
Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the Quarter Ended 30th September 20267 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the Quarter Ending 30th September 202625 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Voting Results and Scrutinizer Report of 89th Annual General Meeting24 Sep 2026 · AGM/EGM / AGM
Proceedings of 89th Annual General Meeting23 Sep 2026 · AGM/EGM / AGM
BRSR Report for the financial year ended March 31, 2026.28 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report of 89th Annual General Meeting to be held on 23rd September 202628 Aug 2026 · Others / Reg. 34 (1) Annual Report
Investor Presentation for the Quarter Ended 30th June 202612 Aug 2026 · Company Update / General
Record Date for the Final Dividend and AGM11 Aug 2026 · Corp. Action / Record Date
Financial Results and Outcome of the Board Meeting11 Aug 2026 · Board Meeting / Outcome of Board Meeting
Additional Details Required for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 20156 Aug 2026 · Company Update / General
Amrutanjan Health Care Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....5 Aug 2026 · Board Meeting / Board Meeting
Commissioning of New Manufacturing Facility5 Aug 2026 · Company Update / General
Announcement under Regulation 30 (LODR)- Credit Rating5 Aug 2026 · Company Update / Credit Rating
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd & Others5 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation of under Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20151 Aug 2026 · Company Update / General
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th June 20268 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for Closure of Trading Window24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Outcome of Postal Ballot19 Jun 2026 · AGM/EGM / Postal Ballot
Voting results and the Scrutinizer Report of the Postal Ballot19 Jun 2026 · AGM/EGM / Postal Ballot
Annual Secretarial Compliance Report for the Financial Year Ended 31.03.202628 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Reconstitution Of Committees of Board of Directors27 May 2026 · Company Update / General
Completion of tenure of Mr. Raja Venkataraman as an Independent Director.26 May 2026 · Company Update / Change in Management
Postal Ballot Notice19 May 2026 · AGM/EGM / Postal Ballot
Notice of Postal Ballot18 May 2026 · AGM/EGM / Postal Ballot
Financial Results - Machine Readable Format13 May 2026 · Company Update / General
Investor Presentation for the Quarter and year ended 31st March 20269 May 2026 · Company Update / Investor Presentation
Intimation on rolling out of the revised Second Phase "ESOP 2" of the existing ESOP Scheme of the Company by the name of "Amrutanjan Health Care Limited - Employee Stock Option Scheme 2020".8 May 2026 · Company Update / General
Re-appointment of Mr. S Muralidharan as Non-Executive Independent Director w.e.f 29 June 2026.8 May 2026 · Company Update / Change in Management
Appointment of Mr. Ramaswami Krishnan as an Additional Director designated as Non-Executive Independent Director w.e.f 8 May 2026.8 May 2026 · Company Update / Change in Management
Outcome of Board Meeting8 May 2026 · Board Meeting / Outcome of Board Meeting
Amrutanjan Health Care Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2026 ,inter alia, to consider and approve Audited Financial Results ....30 Apr 2026 · Board Meeting / Board Meeting
Product Launch17 Apr 2026 · Company Update / General
Rephrasing of ESOP17 Apr 2026 · Company Update / General
Certificate Under Reg.74(5) of SEBI (DP) Regulation 20188 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the Quarter and Year Ending 31st March 202624 Mar 2026 · Insider Trading / SAST / Closure of Trading Window

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 1.0000	6 Nov 2026	7 Nov 2026	—
Final Dividend - Rs. - 2.9000	11 Sep 2026	11 Sep 2026	—
Interim Dividend - Rs. - 1.0000	6 Feb 2026	7 Feb 2026	—
Interim Dividend - Rs. - 1.0000	18 Nov 2025	18 Nov 2025	—
Final Dividend - Rs. - 2.6000	16 Sep 2025	16 Sep 2025	—
Interim Dividend - Rs. - 1.0000	18 Feb 2025	18 Feb 2025	—
Interim Dividend - Rs. - 1.0000	22 Nov 2024	22 Nov 2024	—
Final Dividend - Rs. - 2.6000	13 Sep 2024	—	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
11 Aug 2026 Board Meeting - Financial Results